Osteomyelitis of the jaws in patients with pycnodysostosis: a systematic review

Glória Maria de França a,*, Fernanda Aragão Felix b, Everton Freitas de Morais c, Maurília Raquel de Souto Medeiros c, Ana Cláudia de Macedo Andrade d, a, Hébel Cavalcanti Galvão e a

a Universidade Federal do Rio Grande do Norte (UFRN), Departamento de Odontologia, Programa de Pós-Graduação em Ciências Odontológicas, Área de Concentração em Patologia Oral e Estomatologia, Natal, RN, Brazil
b Universidade Federal do Rio Grande do Norte (UFRN), Centro de Biociências, Programa de Pós-Graduação em Ciências Odontológicas, Área de Concentração em Biologia Oral, Natal, RN, Brazil

Received 8 September 2020; accepted 3 December 2020
Available online 29 January 2021

KEYWORDS
Pycnodysostosis; Cathepsin K; Osteomyelitis; Diagnosis; Jaws

Abstract

Introduction: Pycnodysostosis is a rare autosomal recessive syndrome that provides the abnormal bone metabolism that increases the susceptibility of patients to develop osteomyelitis.

Objective: This systematic review was conducted to analyze the risk factors associated with the development of complications in the jaws (fractures and osteomyelitis), as well as their clinical-pathological characteristics and therapeutic approaches in patients with pycnodysostosis.

Methods: Searches were performed in the PubMed, Web of Science, Scopus, Lilacs, and Cochrane databases. Case reports or case series that met the eligibility criteria according to the PRISMA statement were included. The full texts of 31 articles were retrieved. Twenty of these articles published between 1969 and 2018 were selected, which described 26 cases of osteomyelitis in patients with pycnodysostosis.

Results: The mean age of the patients was 37.84 years; the male-to-female was 1.36:1. The mandible was the most affected site (76.9%). Toth extraction was the main risk factor for osteomyelitis (61.5%), followed by infection (26.6%) and mandibular fracture (23.0%). Antibiotic therapy alone or combined with some surgical procedure was the treatment used in most cases (80.7%).

Conclusion: The findings of this review showed that patients with pycnodysostosis are more likely to develop osteomyelitis of the jaws after surgical procedures, especially tooth extraction which remains the main risk factor for its establishment. In addition, prophylactic antibiotic therapy in the pre- and postoperative periods may prevent the development of osteomyelitis in pycnodysostosis.

© 2021 Associação Brasileira de Otorrinolaringologia e Cirurgia Cérvico-Facial. Published by Elsevier Editora Ltda. This is an open access article under the CC BY license (http://creativecommons.org/licenses/by/4.0/).

* Corresponding author.
E-mail: gloriafracam@gmail.com (G.M. de França).

Peer Review under the responsibility of Associação Brasileira de Otorrinolaringologia e Cirurgia Cérvico-Facial.

https://doi.org/10.1016/j.bjorl.2020.12.009
1808-8694/© 2021 Associação Brasileira de Otorrinolaringologia e Cirurgia Cérvico-Facial. Published by Elsevier Editora Ltda. This is an open access article under the CC BY license (http://creativecommons.org/licenses/by/4.0/).
Introduction

Pycnodysostosis (PYCD) is a rare autosomal recessive syndrome that belongs to the group of bone dysplasias. This disorder is caused by mutations in the CTSG gene located on chromosome 1q21.2 that encodes cathepsin K, a lysosomal cysteine protease present in osteoclasts which participates in the degradation of type I collagen (predominant protein in the bone matrix). Mutations in this gene lead to defective bone metabolism, more specifically deficient bone resorption.2-4

The prevalence of PYCD is 1 in 1.7 million and no sex predilection has been reported.3 Autosomal recessive inheritance is the pattern of transmission of mutations in the CTSG gene that encodes cathepsin K. Thus, parental consanguinity is an important etiological factor.1-5 PYCD is characterized by abnormal bone metabolism, reduced bone elasticity, endocrine and immunological dysfunction and altered extracellular matrix remodeling in organs such as the lung, thyroid and skin.1,3,5

Patients with PYCD commonly exhibit a short-stature phenotype, open bone sutures, short phalanges, bone dysplasia with altered density of the bone matrix, and pathological fractures as a result of reduced elasticity and poor bone healing. Oral manifestations include an obtuse mandibular angle, malocclusion, an osling palate, and dental anomalies.4,6 The abnormal bone metabolism increases the susceptibility of patients to develop osteomyelitis. In gnathic bones, local factors related to the development of osteomyelitis include the bone characteristics of the maxilla and mandible, continuous traumas, alveolar surgical procedures, and conditions that affect the teeth such as periapical and periodontal disease.3-5 It should be emphasized that the treatment of osteomyelitis in gnathic bones is difficult and may require major surgical resections.5

Therefore, the hypothesis of this study is that manipulation of the jaws in patients with PYCD may favor the development of osteomyelitis. This systematic review was conducted to analyze the risk factors associated with the development of complications in the jaws (fractures and osteomyelitis), as well as their clinical-pathological characteristics and therapeutic approaches in patients with PYCD.

Methods

A systematic literature review on PYCD based on the 2009 PRISMA (Preferred reporting items for systematic reviews and meta-analyses) statement10 was conducted on 6 March 2019 to answer the following research question according to the PICO criterion (population, intervention, control, and outcome): “Is surgical manipulation of the jawbones the main risk factor for osteomyelitis in patients with PYCD?”. This systematic literature review was registered in PROSPERO (International prospective register of systematic reviews) under protocol number: CRD42020209580.

The databases selected for the systematic review were PubMed, Web of Science, SCOPUS, Cochrane, and LILACS. The following search terms were used: “Pycnodysostosis” OR “Pycnodysostosis” AND “Surgery, Oral” OR “Maxillofacial Surgery” OR “Oral Surgery” OR “Exodontics” OR “Dentistry, Operative” OR “Surgical Procedures, Oral” OR “Procedure, Oral Surgical” OR “Procedures, Oral Surgical” OR “Surgical Procedure, Oral” OR “Maxillofacial Procedures” OR “Maxillofacial Procedure” OR “Procedure, Maxillofacial” OR “Procedures, Maxillofacial” OR “Tooth extraction” AND “Osteomyelitis” OR “Osteomyelitides” OR “Diseases, Infectious Bone” OR “Bone Diseases, Infectious” OR “Diseases, Infectious Bone” OR “Infectious Bone Disease” OR “Infectious Bone Diseases” (Supplementary Table 1).

The criteria for inclusion were published studies specifically investigating osteomyelitis of the jaws in patients with PYCD. Only case reports and case series were included. Excluded were studies that did not address osteomyelitis as a complication in the jaws, studies addressing osteomyelitis in bones other than the jaws, articles that did not report the primary cause of osteomyelitis, studies based on animal models, in vitro studies, editorial letters, review articles, and studies whose full text was not available through inter-library loan.

The articles were selected independently by two of the authors. First, the authors selected articles by reading the title and abstract, according to the established inclusion and exclusion criteria. Articles not related to the topic were excluded. The full text of the remaining studies was downloaded, and the articles were selected based on the eligibility criteria. Articles whose full text was not available were excluded and the final sample of studies for qualitative synthesis was determined. Discrepancies were resolved by a third author.

The eligible studies were reviewed and the following data were extracted: (1) authors and year of publication; (2) number of patients; (3) sex and age (mean) of the patient; (4) cause; (5) clinical (family history, location, symptoms) and radiographic characteristics; (6) therapeutic intervention and outcome, (7) and patient follow-up. The reviewers did not disagree on the selection of the articles. The methodological quality of the articles was evaluated according to the CARE guidelines for case reports, a qualitative checklist for observational studies and case reports.

Results

Overall results

The electronic database search was last updated in March 2019 and yielded 50,986 records: 47,779 from PubMed, 3197 from Web of Science, 4 from LILACS, 6 from SCOPUS, and 0 from The Cochrane Library. A total of 49,798 records were obtained after the removal of duplicates, which were screened according to the inclusion and exclusion criteria. At this stage, 31 articles were considered relevant to the topic (the other 49,767 studies did not specifically address PYCD). The full texts of these 31 articles were then assessed for eligibility, leading to the inclusion of 20 studies. The flow chart of the study selection process adapted from the PRISMA statement is shown in Fig. 1. Finally, 20 articles published between 1969 and 2018 were retrieved by the authors, corresponding to 26 cases of osteomyelitis in PYCD. The etiological, clinical, histological, biological, and therapeutic data for each of the 26 patients included in the study were analyzed. Due to the heterogeneity of the available liter-
Figure 1 Flow chart of the database search and article selection process according to PRISMA.

Quality assessment

The quality of the articles was established using the CARE guidelines for case reports (2013) and the results are shown in Table 1. Of the 29 items of the CARE checklist (2013), the study of Kirita et al.11 adhered to the largest number of items (20 items), followed by the studies of Kamat et al.,12 Fénelon et al.12 (18 items), Kato et al.,13 and Frota et al.14 (17 items). In contrast, the case reports by Emami-Ahari et al.15 and Dimitrakopoulos et al.16 adhered to only few items (6 and 8 items, respectively). The clinical findings topic was the most frequently reported item, which was described in all articles (n = 20). On the other hand, the prognosis item was not addressed by any of the studies. The item “diagnostic reasoning including other diagnoses considered” was only reported in the study of Dhameliya et al.17

Epidemiology and causal factors

Twenty-six cases of osteomyelitis of the jaws related to PYCD were described in the 20 selected articles. Men were more commonly affected (n = 15) than women (n = 11), with a male-to-female ratio of 1.36:1. The age of the patients ranged from 21 to 55 years (mean of 37.84 ± 9.58 years), as described in Table 2.

The family history of PYCD was not reported in eight articles, corresponding to 11 cases without information. Most of the articles in which this information was available
reported consanguinity or a family history of the disease: siblings (n = 6), children of consanguineous parents, especially cousins (n = 4) and paternal aunt (n = 1). Six patients had no family history of the disease.

The medical history revealed a history of some type of bone fracture, especially in the long bones (n = 9). The bone fractures involved the femur (n = 4), tibia (n = 3), elbows (n = 3), ribs (n = 2), hip (n = 2), clavicle (n = 1), scapula (n = 1), and knee (n = 1). Two patients had a history of hydrocephalus.

Among the 26 cases of osteomyelitis related to PYCD found in the literature, tooth extraction was the main risk factor in 16 cases (61.5%), followed by a history of jaw fracture (n = 6, 23.0%) and the presence of infection such as caries (n = 3, 11.5%) and periodontal diseases (n = 3, 11.5%). The simultaneous presence of caries and periodontal lesions was observed in one case (3.8%), as shown in Fig. 2. All risk factors for osteomyelitis development are illustrated in Fig. 3.

### Table 1: Quality assessment to CARE checklist.

| Topic                  | Item    | Description                                                                 | Percentage of case reports |
|------------------------|---------|-----------------------------------------------------------------------------|-----------------------------|
| Title                  | 1       | The words ‘‘case report’’ should be in the title along with the area of focus | 7                           |
| Keywords               | 2       | 2 to 5 keywords that identify areas covered in this case report             | 10                          |
| Abstract               | 3a      | Introduction - What is unique about this case? What does it add to the medical literature? | 5                           |
|                        | 3b      | The main symptoms of the patient and the important clinical findings        | 6                           |
|                        | 3c      | The main diagnoses, therapeutics interventions, and outcomes                | 6                           |
|                        | 3d      | Conclusion – What are the main ‘‘take-away’’ lessons from this case?        | 5                           |
| Introduction           | 4       | One or two paragraphs summarizing why this case is unique with references.  | 17                          |
| Patient information    | 5a      | De-identified demographic information and other patient specific information.| 13                          |
|                        | 5b      | Main concerns and symptoms of the patient.                                 | 16                          |
|                        | 5c      | Medical, family, and psychosocial history including relevant genetic        | 15                          |
|                        |         | information (also see timeline)                                            |                             |
|                        | 5d      | Relevant past interventions and their outcomes                             | 13                          |
| Clinical findings      | 6       | Describe the relevant Physical Examination (PE) and other significant clinical findings | 20                          |
| Timeline               | 7       | Important information from the patient’s history organized as a timeline     | 16                          |
| Diagnostic assessment  | 8a      | Diagnostic methods (such as PE, laboratory testing, imaging, surveys)      | 17                          |
|                        | 8b      | Diagnostic challenges (such as access, financial, or cultural)              | 1                           |
|                        | 8c      | Diagnostic reasoning including other diagnoses considered                    | 1                           |
|                        | 8d      | Prognostic characteristics (such as staging in oncology) where applicable     | 0                           |
| Therapeutic intervention| 9a     | Types of intervention (such as pharmacologic, surgical, preventive, self-care)| 18                          |
|                        | 9b      | Administration of intervention (such as dosage, strength, duration)         | 10                          |
|                        | 9c      | Changes in intervention (with rationale)                                    | 2                           |
| Follow-up and outcomes | 10a     | Clinician and patient-assessed outcomes (when appropriate)                  | 13                          |
|                        | 10b     | Important follow-up diagnostic and other test results                        | 9                           |
|                        | 10c     | Intervention adherence and tolerability (How was this assessed?)             | 4                           |
|                        | 10d     | Adverse and unanticipated events                                            | 4                           |
| Discussion             | 11a     | Discussion of the strengths and limitations in your approach to this case   | 4                           |
|                        | 11b     | Discussion of the relevant medical literature                               | 13                          |
|                        | 11c     | The rationale for conclusions (including assessment of possible causes)     | 13                          |
|                        | 11d     | The primary ‘‘take-away’’ lessons of this case report                        | 3                           |
| Patient perspective    | 12      | When appropriate the patient should share their perspective on the treatments, they received | 3                           |

### Clinical and radiographic characteristics

Regarding the anatomical location, there was a slight predominance of osteomyelitis in the mandible (n = 20, 76.9%) over the maxilla (n = 4, 15.4%). Both jaws were affected in two cases (7.7%). The most common symptoms were swelling and edema (n = 12), followed by pain (n = 11), purulent discharge (n = 9), presence of a fistula (n = 5), and trismus (n = 1). Information about symptoms was not available in two cases.

As radiographic characteristics, osteomyelitis was accompanied by bone sequestrum (n = 16), osteolysis (n = 7), radiolucency (n = 2), and ill-defined borders (n = 2). Increased bone density (osteosclerosis) was observed in 11 of the cases and was the most common pattern after bone sequestrum. In four cases, fracture of the jaws was demonstrated by radiography. Hypercementosis involving the permanent teeth was seen in three cases.
Table 2 Etiology, Clinical and radiographic characteristics of the 27 cases of osteomyelites in patients with pycnodysostosis.

| Parameters                        | n  | %   |
|-----------------------------------|----|-----|
| N° de casos                       | 26 | 100.0 |
| Age                               |    |     |
| Range                             | 21-55 years old |     |
| Media                             | 37.84 |     |
| Standard deviation                | 9.58 |     |
| Gender                            |    |     |
| Female                            | 11 | 42.3 |
| Male                              | 15 | 57.7 |
| Family history*                   |    |     |
| Consanguineous marriage           | 4  | 15.4 |
| Siblings                          | 6  | 23.0 |
| Aunt                              | 1  | 3.8  |
| No family history                 | 6  | 23.0 |
| NA                                | 11 | 42.3 |
| Medical history*                  |    |     |
| Fractures of the long bones       | 9  | 34.6 |
| Femoral fracture                  | 4  | 15.4 |
| Tibial fractures                  | 3  | 11.5 |
| Elbows                            | 3  | 11.5 |
| Rib                               | 2  | 7.7  |
| Hip                               | 2  | 7.7  |
| Clavicle                          | 1  | 3.8  |
| Shoulder blade                    | 1  | 3.8  |
| Knee                              | 1  | 3.8  |
| Hydrocephalus                     | 2  | 7.7  |
| NA                                | 7  | 26.9 |
| Promoter factor*                  |    |     |
| Tooth exodontics                  | 16 | 61.5 |
| Jaw fracture                      | 6  | 23.0 |
| Carie                             | 3  | 11.5 |

Table 2 (Continued)

| Parameters                        | n  | %   |
|-----------------------------------|----|-----|
| Periodontal disease               | 3  | 11.5 |
| Carie and periodontal disease     | 1  | 3.8  |
| Anatomical location               |    |     |
| Maxila                            | 4  | 15.4 |
| Mandibula                         | 20 | 76.9 |
| Maxila e mandibula                | 2  | 7.7  |
| Symptomatology*                   |    |     |
| Swelling                          | 12 | 46.1 |
| Pain                              | 11 | 42.3 |
| Purulent secretion                | 9  | 34.6 |
| Fistula                           | 5  | 19.2 |
| Trismus                           | 1  | 3.8  |
| No symptomatology                 | 1  | 3.8  |
| NA                                | 2  | 7.7  |
| Radiographic features*            |    |     |
| Sequestrum                        | 16 | 61.5 |
| Osteolysis                        | 7  | 26.9 |
| Radiolucence                      | 2  | 7.7  |
| Poorly defined edges              | 2  | 7.7  |
| Osteosclerosis                    | 11 | 42.3 |
| Jaw fracture                      | 4  | 15.4 |
| Hipercementosis                   | 3  | 11.5 |
| Treatment*                        |    |     |
| Antibiotic therapy                | 21 | 80.7 |
| Sequestrectomy                    | 14 | 53.8 |
| Curettage                         | 8  | 30.7 |
| Tooth extraction                  | 4  | 15.4 |
| Resection                         | 2  | 7.7  |
| Jaw reconstruction                | 5  | 19.2 |
| NA                                | 1  | 3.8  |
| Follow-up                         |    |     |
| Present in                         | 17 | 65.4 |
Table 2 (Continued)

| Parameters          | n   | %   |
|---------------------|-----|-----|
| Range               | 6–168 months |     |
| Media               | 28.46 |     |
| Standard deviation  | 39.80 |     |
| NA                  | 9   | 34.6|

NA, Not available. * Patients present more than one category in the group.

Therapeutic interventions and followup

The treatment of osteomyelitis ranged from conservative (antibiotic therapy and curettage) to more radical approaches (tooth extraction, sequestrectomy, and resection). Antibiotic therapy was the treatment of choice in 21 cases, followed by sequestrectomy (n = 14), curettage (n = 8), tooth extraction (n = 4), and resection (n = 2).

Of the 21 cases receiving antibiotic therapy, thirteen of them specified the antibiotic used, although only eight reported the dosage and time used (Supplementary Table 2). Culture and antibiogram were performed in 3 articles, including carbenicillin and ampicillin,\(^{13}\) clindamycin,\(^{14}\) moxifloxacin (400 mg once daily), injection cefotaxime sodium (1 g twice daily), and injection metronidazole (500 mg thrice daily).\(^{2}\) Within the penicillin group, the use of penicillin G with an average concentration of 11.2 IU was selected in four of the cases.\(^{16,19,20}\) Amoxicillin with 500 mg regimen, 3× daily for 5 days, was used in one case;\(^{10}\) in another case,\(^{16}\) the authors also used ampicillin, but did not specify the adopted regimen. The use of amoxicillin 1 g, 2× daily for 15 days, was adopted in two cases.\(^{12}\) In addition, flucloxacillin and ticarcillin-clavulanato were used in one case each, although the regimen was not specified.\(^{21,22}\) In the lincomamide class, clindamycin 300 mg was the drug of choice, with a 4× daily regimen for 14 days in one case,\(^{4}\) although in the other two articles the regimen was not specified.\(^{14,21}\)

Figure 3  Etiology of osteomyelitis in patients with pycnodysostosis. (A) Osteoclasts release H⁺ and cathepsin K into How ship lacunae during tooth extraction in patients with normal bone density. (B) After bone resorption, osteoblasts are attracted to the site and initiate the process of bone neoformation. (C) Newly formed bone. (D) In the absence of cathepsin K, osteoclasts act inefficiently, leading to acid medium. Patients with osteosclerosis are more susceptible to fractures in response to small traumas because of reduced bone vascularization. (E) The presence of microorganisms, the acid medium and the impairment of bone turnover cause the formation of bone sequestrum. (F) Caries and periodontal disease induce the release of inflammatory mediators and microbial products and associated with impaired osteoclast activity, promote osteomyelitis in patients with pycnodysostosis.
in addition to lincomycin 500mg for 10 days, used in one case.23

In five cases, the treatment of choice was accompanied by reconstruction of the jawbones. In some cases, prophylactic antibiotic therapy was administered in combination with curettage, extraction, sequestrectomy and resection.14 The time of followup was reported in 17 cases and ranged from 6 to 168 months, with a mean of 28.46 ± 39.8 months.

**Discussion**

The osteoclasts of patients with PYCD are unable to degrade collagen I and other non-collagenous proteins that form the bone matrix, while these cells maintain their demineralizing activity, resulting in abnormal bone metabolism.24,25 The absence of cathepsin K also seems to stimulate cortical bone formation through the negative control of periostin secreted by osteoblasts and osteocytes, a fact that explains the apparent contradictory effect of the increased bone density in PYCD, demonstrated by the presence of osteosclerosis. The latter was observed in 11/26 patients.12,14,16,19,22

The bone quality in patients with PYCD is low (fragile and poorly organized matrix). Bone strength is reduced due to acidification, increasing the risk of fractures, particularly in the lower extremities.26,27 (Fig. 3D). The present study demonstrated fractures in the long bones of 9/26 patients, corroborating the findings of enhanced mechanical sensitivity and an increased fracture risk in patients with PYCD. These can be explained by the fact that cathepsin K is important for bone resorption in bones with a high turnover rate (e.g., long bones). The present study demonstrated osteolytic lesions in 7/26 patients.11,13,14,16,19,22

The manifestation of osteomyelitis depends on the virulence factors of microorganisms, immune system and vascular factors of the patient. Increased susceptibility to osteomyelitis of the mandible is attributed to the increased bone density (osteosclerosis) favors the establishment of osteomyelitis, which has fewer medullary spaces and a single neurovascular bundle.11 Our results were consistent with the literature, with the mandible being the most affected site (n = 22).7,26,6,11-15,17-23,27-30

In the maxillary bones, osteomyelitis is commonly caused by the dissemination of an odontogenic infection (n = 7)7,11,12,16,17,29 or by surgical traumas (n = 16)7,5,6,13-15,18-23,27,28,30 Since the oral cavity harbors commensal microorganisms, diseases and manipulation of the teeth can create a route for microorganisms to enter the bone.8,31 Once it has reached the bone, the inflammatory response may culminate in the production of pus, increasing the intramedulary pressure and reducing blood flow into the bones. An increase in ischemic and necrotic bone contributes to the establishment of infection, demonstrated by the presence of bone sequestrum. The presence of pus can even compromise the integrity of cortical bone. The involvement of soft tissues is often observed, which is indicated by local edema (12/26)7,5,11,13,14,16,17,19,20,23,29 and by intra- or extraoral fistulas,8 as found in 5/26 of the reported cases.14,15,19,23 Purulent secretion was a finding in 9/26 cases,2,5,11,15,17,18,21 Pain (11/26)7,6,12,16,19,20,22,28,29 and trismus (1/26)20 characteristic of chronic osteomyelitis, the most common type observed in the present study, were also reported.

This study demonstrated that tooth extraction was the main risk factor of osteomyelitis. Such procedures are known to break down the bone barrier and to create a portal of entry for microorganisms that then populate the bone component. In addition, tooth extraction is a traumatic event that, in conjunction with the defective bone matrix in PYCD, favors the occurrence of bone fractures (Fig. 3E). Radiography revealed fractures in four cases.13,15,17,21

Osteomyelitis was reported in association with periodontitis in 4/26 cases.15,16,21 Periodontitis is a common oral inflammatory disease.33 There is evidence indicating that the inhibition of cathepsin K results in the suppression of immune system cells and in the reduction of osteoclast activity, reducing the malnutrition of alveolar bone in periodontitis (Fig. 3F). Periodontitis may occur in patients with PYCD and can be the primary cause of osteomyelitis, as highlighted in the present study.

Investigation of the role of cathepsin K in periapical diseases demonstrates that this protease is involved in bone resorption and immune system activation, as well as in events during establishment of the immune response related to the recognition of microorganisms by Toll-Like Receptors (TLR) on dendritic cells.34 In PYCD, patients therefore lack mechanisms related to the limitation of infection (an effective immune response), a fact favoring the invasion of medullary tissues and the development of osteomyelitis, which was reported in association with pulp events in 4/26 cases.5,12,16,17

Antimicrobial therapy and surgical debridement are the main treatment modalities for osteomyelitis.8,35 Despite advances in surgical procedures and chemotherapy, osteomyelitis remains difficult to treat and there is no universally accepted treatment protocol.8 In the cases of this systematic review, antibiotic therapy was the treatment of choice in patients with osteomyelitis associated with PYCD. This treatment was administered alone in three articles,2,12,22 or combined with some surgical procedure in 15 articles.5,6,11,12,14-16,18-23,29,30 The antibiotic and treatment regime used were specified in most cases.

Culture and antibiogram are laboratory support mechanisms used to reliably determine the causative agent of infection and the most efficient antibiotic therapy to combat it. This procedure was performed in three of the cases of this review.2,14,18 In most articles, the antibiotic regimen was combined with the use of two or more medications, including different administration routes (intramuscular, oral, intravenous and topical).16,18-21 Penicillin was the antibiotic of choice in most cases, although in one of the reported cases the antibiogram determined resistance to this antibiotic.3 In cultured cases, the antibiotic of choice was variable, including penicillin (carbenicillin and ampicillin), lincomamides (clindamycine), fluoroquinolones (moxifloxacin), cephalosporins (cefotaxime) and nitroimida- zole (metronidazole) antibiotics.2,14,18

It is argued that radical treatments should be avoided in the management of osteomyelitis associated with PYCD because of the risk of trans- and postoperative complications. In four cases,2,5,16,17 the patients refused the surgical approach proposed and chose more conservative treatments. Four of the patients undergoing more invasive
treatment developed subsequent complications.\textsuperscript{11,18,19,21} Patient-reported adherence, accessibility and tolerability of the adopted treatment should be considered, as done in four articles.\textsuperscript{2,6,12,22} The change of the adopted treatment in the case of unexpected side effects or recurrence, as reported in seven articles,\textsuperscript{2,11,12,18,19,21,22} is also important. Finally, the literature reports that pre- (antibiotic prophylaxis) and postoperative antibiotic therapy avoids postoperative complications of invasive dental procedures. In addition, these procedures favor tissue repair in the surgical region, subgingival scraping, and necropultecomas.\textsuperscript{36,37}

Conclusion

The findings of this review showed that patients with PYCD are more likely to develop osteomyelitis of the jaws, especially after tooth extraction and configure the main risk factor for its establishment. Whenever possible, pre- (antibiotic prophylaxis) and postoperative antibiotic therapy seems to be appropriate in patients with PYCD until complete tissue healing, even in the case of minor procedures, in order to avoid complications such as osteomyelitis and pathological fractures. In addition, more conservative osteomyelitis treatment should be chosen to prevent additional trauma to the jaws.

Funding

The work was supported by the Department of Dentistry, Oral Pathology Postgraduate Program, Brazil.

Conflicts of interest

The authors declare no conflicts of interest.

Acknowledgements

This work was carried out with the support of the Coordenação de Aperfeiçoamento de Pessoal de Nível Superior – Brazil (CAPES) – financing code 001.

Appendix A. Supplementary data

Supplementary material related to this article can be found, in the online version, at doi:https://doi.org/10.1016/j.bjorl.2020.12.009.

References

1. Xue Y, Cai T, Shi S, Wang W, Zhang Y, Mao T, et al. Clinical and animal research findings in pyknodysostosis and gene mutations of cathepsin K from 1996 to 2011. Orphanet J Rare Dis. 2011;6:20.
2. Kamat S, Sankar K, Eswari NJ, Gahlawat V, Jude BJ, Megh A. Management of chronic suppressive osteomyelitis in a patient with pyknodysostosis by intra-lesional antibiotic therapy. J Nat Sc Biol Med. 2015;6:464–7.
3. Fujita Y, Nakata K, Yasui N, Matsui Y, Kataoka E, Hiroshima K, et al. Novel mutations of the cathepsin K gene in patients with pyknodysostosis and their characterization. J Clin Endocrinol Metab. 2000;85:425–31.
4. Soliman AT, Ramadan MA, Sheriff A, Aziz Bedair ES, Rizk MM. Pyknodysostosis: clinical, radiologic, and endocrine evaluation and linear growth after growth hormone therapy. Metabolism. 2001;50:905–11.
5. Rohit S, Reddy BP, Sreedevi B, Prakash S. Osteomyelitis in pyk- nodysostosis: review of 2 clinical cases. J Clin Diagn Res. 2015;9:15–7.
6. Oliveira EM, Arruda JAA, Nascimento PAM, Neiva IM, Mesquita RA, Souza LN. An update on osteomyelitis treatment in a pyknodysostosis patient. J Oral Maxillofac Surg. 2018;76:2136.e1–10.
7. Maffulli N, Papalia CR, Zampogna CB, Torre CG, Albo CE, Denaro V. The management of osteomyelitis in the adult. Surgeon. 2016;14:345–60.
8. Dym H, Zeidan J. Microbiology of acute and chronic osteomyelitis and antibiotic treatment. Dent Clin N Am. 2017;61:271–82.
9. Liu D, Zhang J, Li T, Li C, Liu X, Zheng J, et al. Chronic osteomyelitis with proliferative periostitis of the mandibular body: report of a case and review of the literature. Ann R Coll Surg Engl. 2019;101:328–32.
10. Moher D, Liberati A, Tetzlaff J, Altman DG, PRISMA Group. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. Int J Surg. 2010;8:336–41.
11. Kiriti T, Sugtiara T, Horiiuchi K, Morimoto H, Yagima H, Sugimura M. Mandibular reconstruction using a vascularised fibula osteocutaneous flap in a patient with pyknodysostosis. Br J Plast Surg. 2001;54:712–4.
12. Fénélon M, Catros S, Boisramé S, D’Incau E, Tréguer A, Gobel Y, et al. Complications maxillo-faciales associées à la pyk- nodysostose: présentation de deux cas cliniques et revue de la littérature. Med Buccale Chir Buccale. 2010;21:169–76.
13. Kato H, Matsuokab K, Katoc N, Ohkubob T. Mandibular osteomyelitis and fracture successfully treated with vascularised iliac bone graft in a patient with pyknodysostosis. Br J Plast Surg. 2005;58:263–6.
14. Frota R, Linard RA, Silva EDO, Antunes AA, Carvalho RWF, Santos TS. Mandibular osteomyelitis and fracture in a patient with pyknodysostosis. J Craniofac Surg. 2010;21:787–9.
15. Emami-Ahari Z, Zarabi M, Javid B. Pyknodysostosis. J Bone Joint Surg Br. 1969;51:307–12.
16. Dimitrakopoulos I, Magopoulos C, Katopodi T. Mandibular osteomyelitis in a patient with pyknodysostosis: A case report of a 50-year misdiagnosis. J Oral Maxillofac Surg. 2007;65:580–5.
17. Dhameliya MD, Dinkar AD, Khorate M, Desai SSR. Pyknodysostosis: Clinico-radiographic report of a rare case. Contemp Clin Dent. 2017;8:134–8.
18. Zachariades N, Koundouris J. Maxillofacial symptoms in two patients with pyknodysostosis. J Oral Maxillofac Surg. 2004;62:919–22.
19. Van Merkheseyn JPR, Bras J, Vermeeren JLF, Sar AVD, Eps WSV. Osteomyelitis of the jaws in pyknodysostosis. Int. J. Oral Max- illofac. Surg. 1987;16:615–9.
20. Allibhai ZA, Mateev MNN, Chindia ML, Moshy J. Presentation and management of chronic osteomyelitis in an African patient with pyknodysostosis. Oral Dis. 1999;5:87–9.
21. Green AE, Rowe NL. Pyknodysostosis—A rare disorder complicating extraction. Br J Oral Surg. 1976;13:254–63.
22. Schmitz JP, Gassmann CJ, Bauer A, Smith BR. Mandibular recon- struction in a patient with pyknodysostosis. J Oral Maxillofac Surg. 1996;54:513–7.
23. Iwu CO. Bilateral osteomyelitis of the mandible in pyknodysos- tosis. A case report. Int. J. Oral Maxillofac. Surg. 1991;20:71–2.
24. Drake MT, Clarke BL, Oursler MJ, Kholsa S. Cathepsin K inhibitors for osteoporosis: biology, potential clinical utility, and lessons learned. Endocr Rev. 2017;38:325–50.
25. Brömme D, Panwar P, Turan S. Cathepsin K osteoporosis trials, pyknodysostosis and mouse deficiency models: commonalities and differences. Expert Opin Drug Discov. 2016;11:457–72.
26. Bonnet N, Brun J, Rousseau JC, Duong LT, Ferrari SL. Cathepsin K controls cortical bone formation by degrading periostin. J Bone Miner Res. 2017;32:1432–41.

27. Mills KL, Johnston AW. Pycnodysostosis. J Med Genet. 1988;25:550–3.

28. Muto T, Michiya H, Taira H, Murase H, Kanazawa M. Pycnodysostosis: report of a case and review of the Japanese literature, with emphasis on oral and maxillofacial findings. Oral Surg, Oral Med, Oral Pathol. 1991;72:449–55.

29. Bathi RJ, Masur VN. Pycnodysostosis – a report of two cases with a brief review of the literature. Int. J. Oral Maxillofac. Surg. 2000;29:439–42.

30. Yamada N, Inomata H, Morita K. Two cases of pycnodysostosis with special emphasis on maxillo-facial findings. Dentomaxillofac Radiol. 1973;2:12–7.

31. Beck-Broichsitter BE, Smeets R, Heiland M. Current concepts in pathogenesis of acute and chronic osteomyelitis. Curr Opin Infect Dis. 2015;28:240–5.

32. Pincus DJ, Armstrong MB, Thaller ESR. Osteomyelitis of the craniofacial skeleton. In: Seminars in plastic surgery. Semin Plast Surg. 2009;23:73–9.

33. Hao L, Zhu G, Lu Y, Wang M, Jules J, Zhou X, et al. Deficiency of cathepsin K prevents inflammation and bone erosion in rheumatoid arthritis and periodontitis and reveals its shared osteoimmune role. FEBS Lett. 2015;589:1331–9.

34. Hao L, Chen W, McConnell M, Zhu Z, Li S, Reddy M, et al. A small molecule, odanacatib, inhibits inflammation and bone loss caused by endodontic disease. Infection and immunity. 2015;83:1235–45.

35. Lima ALL, Oliveira PR, Carvalho VC, Cimerman S, Savio E. Recommendations for the treatment of osteomyelitis. Braz J Infect Dis. 2014;18:526–34.

36. Da Silva VP, Visioli F, Maraschin BJ, Cardoso JA, Falcão GGVSC, Oliveira MC, et al. Oral Lesions in Pycnodysostosis Syndrome: Eleven Years of Follow-Up. J Craniofac Surg. 2016;27:617–8.

37. Ortegosa Mv, Bertola Dr, Aguena M, Passos-Bueno Mr, Kim Ca, de Faria Mej. Challenges in the Orthodontic Treatment of a Patient With Pycnodysostosis. Cleft Palate Craniofac J. 2014;51:735–9.